2020
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomes
2017
An explanatory factor analysis of a brief self-report scale to detect neurocognitive impairment among HIV-positive men who have sex with men and transgender women in Peru
Weikum D, Shrestha R, Ferro EG, Vagenas P, Copenhaver M, Spudich S, Alpert MD, Cabello R, Lama JR, Sanchez J, Altice FL. An explanatory factor analysis of a brief self-report scale to detect neurocognitive impairment among HIV-positive men who have sex with men and transgender women in Peru. AIDS Care 2017, 29: 1297-1301. PMID: 28449599, PMCID: PMC6337065, DOI: 10.1080/09540121.2017.1322681.Peer-Reviewed Original ResearchConceptsHIV-positive menNeuropsychological Impairment ScaleNeurocognitive impairmentTransgender womenAntiretroviral therapyHIV-positive MSMPoor clinical outcomeHIV risk behaviorsClinical care settingsHealth-related outcomesExploratory factor analysisART adherenceClinical outcomesPatient populationCare settingsImpairment ScaleRisk behaviorsImpairmentMenPrincipal axis factoringSelf-report scalesOrthogonal varimax rotationWomenBrief self-report scaleOutcomes
2016
Community-Based Interventions to Improve and Sustain Antiretroviral Therapy Adherence, Retention in HIV Care and Clinical Outcomes in Low- and Middle-Income Countries for Achieving the UNAIDS 90-90-90 Targets
Nachega JB, Adetokunboh O, Uthman OA, Knowlton AW, Altice FL, Schechter M, Galárraga O, Geng E, Peltzer K, Chang LW, Van Cutsem G, Jaffar SS, Ford N, Mellins CA, Remien RH, Mills EJ. Community-Based Interventions to Improve and Sustain Antiretroviral Therapy Adherence, Retention in HIV Care and Clinical Outcomes in Low- and Middle-Income Countries for Achieving the UNAIDS 90-90-90 Targets. Current HIV/AIDS Reports 2016, 13: 241-255. PMID: 27475643, PMCID: PMC5357578, DOI: 10.1007/s11904-016-0325-9.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsCommunity Health CentersCross-Sectional StudiesDeveloping CountriesHealth EducationHealth Services AccessibilityHIV InfectionsHumansMedication AdherenceObservational Studies as TopicPatient DropoutsRandomized Controlled Trials as TopicSustained Virologic ResponseUnited NationsConceptsHealth facility-based interventionsFacility-based interventionsAntiretroviral therapy adherenceCommunity-based interventionsVirologic suppressionCohort studyMiddle-income countriesClinical outcomesTherapy adherenceRelative riskComparable outcomesCommunity-based ART delivery modelTreatment engagementART delivery modelsFacility-based modelsComparative cohort studyRelevant clinical outcomesRandom-effects modelLeast comparable outcomesStable HIVCause mortalityHIV careART adherenceUNAIDS 90ART delivery
2011
Improving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine
Korthuis PT, Fiellin DA, Fu R, Lum PJ, Altice FL, Sohler N, Tozzi MJ, Asch SM, Botsko M, Fishl M, Flanigan TP, Boverman J, McCarty D. Improving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s83-s90. PMID: 21317600, PMCID: PMC3066190, DOI: 10.1097/qai.0b013e31820bc9a5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBuprenorphineBuprenorphine, Naloxone Drug CombinationCohort StudiesFemaleGuideline AdherenceHIV InfectionsHumansMaleMiddle AgedMultivariate AnalysisNaloxoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPractice Guidelines as TopicQuality of Health CareConceptsBUP/NXHIV careOpioid dependenceHIV qualitySummary quality scoresCare indicatorsBuprenorphine/naloxone maintenance therapyHigh-quality HIV careOpioid-dependent HIVRole of buprenorphineObservational cohort studyOpioid-dependent patientsQuality scoresNondependent patientsHIV clinicMaintenance therapyCohort studyBuprenorphine treatmentClinical outcomesMultivariable analysisMedical recordsPatientsCareMonthsHIVMedication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research
Bae JW, Guyer W, Grimm K, Altice FL. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS 2011, 25: 279-290. PMID: 21239892, DOI: 10.1097/qad.0b013e328340feb0.Peer-Reviewed Original ResearchConceptsClinical outcomesPrescribed therapyFuture clinical careSuboptimal persistenceVirological failureAntiretroviral resistanceMedication persistenceHIV infectionMedication treatmentHIV treatmentCertain regimensClinical consequencesClinical carePatient behaviorPatientsContinuous treatmentUnderrecognized aspectsTherapyAdherenceHIVTreatmentShort durationCurrent literatureDurationIntervention
2008
Clinical Outcomes of Hepatitis C Treatment in a Prison Setting: Feasibility and Effectiveness for Challenging Treatment Populations
Maru DS, Bruce RD, Basu S, Altice FL. Clinical Outcomes of Hepatitis C Treatment in a Prison Setting: Feasibility and Effectiveness for Challenging Treatment Populations. Clinical Infectious Diseases 2008, 47: 952-961. PMID: 18715156, PMCID: PMC4847716, DOI: 10.1086/591707.Peer-Reviewed Original ResearchConceptsSustained virological responseRate of prescriptionVirological responsePEG-RBVBaseline HCV RNA levelHepatic C virus infectionHCV genotype 1 infectionBaseline major depressionC virus infectionChronic HCV infectionHCV RNA levelsTreatment-naive patientsGenotype 1 infectionHepatitis C treatmentOutcome of treatmentUse of medicationsNewer mood stabilizersHCV infectionHIV infectionClinical outcomesMood stabilizersAntipsychotic medicationBlack raceClinical effectivenessMajor depression
2007
Directly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance
Maru DS, Kozal MJ, Bruce RD, Springer SA, Altice FL. Directly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2007, 46: 555-563. PMID: 18193497, PMCID: PMC2684061, DOI: 10.1097/qai.0b013e318158c0bd.Peer-Reviewed Original ResearchConceptsDrug resistance mutationsNew drug resistance mutationsSelf-administered therapyDrug usersAntiretroviral therapyHIV genotypic resistance testingFuture drug optionsAntiretroviral drug resistanceGenotypic resistance testingGenotypic sensitivity scoreMain outcome measuresMedication resistanceModified intentionVirologic benefitAntiretroviral resistanceTreat analysisClinical outcomesDrug mutationsDrug optionsOutcome measuresAdjusted probabilityDrug resistanceResistance mutationsHIVEffective interventionsClinical Care of the HIV-Infected Drug User
Bruce RD, Altice FL. Clinical Care of the HIV-Infected Drug User. Infectious Disease Clinics Of North America 2007, 21: 149-179. PMID: 17502234, PMCID: PMC2128697, DOI: 10.1016/j.idc.2007.03.009.Peer-Reviewed Original Research
2006
Models for Integrating Buprenorphine Therapy into the Primary HIV Care Setting
Basu S, Rohrberg D, Bruce RD, Altice FL. Models for Integrating Buprenorphine Therapy into the Primary HIV Care Setting. Clinical Infectious Diseases 2006, 42: 716-721. PMID: 16447120, DOI: 10.1086/500200.Peer-Reviewed Original ResearchConceptsBuprenorphine maintenance therapyHIV care settingsMaintenance therapyHIV servicesCare settingsPrimary HIV care settingsSite specialistHIV care providersInjection drug useHuman immunodeficiency virusNegative clinical outcomesPrimary care modelDrug treatment modelAntiretroviral therapyHIV careBuprenorphine therapyClinical outcomesImmunodeficiency virusClinic settingOpiate useCare modelCare providersOpiate dependenceDrug useTherapy services